Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results